Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Invitae Corporation
More than 75 industry executives and experts gazed into the crystal ball and shared with Scrip their predictions around transformative technologies. Perhaps unsurprisingly, AI was the dominant theme – but gene editing, cell therapies and new targeting modalities were also among the highlights.
Natera has pounced on the opportunity to purchase Invitae’s reproductive health assets at a bargain price, simultaneously quashing any potential ongoing royalty payments between the two.
Nucleic acid-based therapies are poised to revolutionize medicine – just as antibodies did thirty years ago.
The approval for Invitae’s cancer risk diagnostic test opens the door for more tests of its kind.
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Other Names / Subsidiaries
- CombiMatrix Corporation
- Clear Genetics
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.